IPD Stock Overview A medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImpediMed Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for ImpediMed Historical stock prices Current Share Price AU$0.053 52 Week High AU$0.12 52 Week Low AU$0.043 Beta 2.88 1 Month Change 0.94% 3 Month Change -2.73% 1 Year Change -44.27% 3 Year Change -69.43% 5 Year Change -51.36% Change since IPO -71.08%
Recent News & Updates
ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025 Jan 28
Less than half of directors are independent Dec 24
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30 See more updates
ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025 Jan 28
Less than half of directors are independent Dec 24
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23
Forecast to breakeven in 2026 Jul 30 ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director Jun 08
New minor risk - Market cap size Jun 04
Independent Non-Executive Director recently bought AU$50k worth of stock May 15
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 Apr 20
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting Apr 11
Independent Non-Executive Director recently bought AU$100k worth of stock Mar 28
Independent Non-Executive Director recently bought AU$90k worth of stock Mar 02
No longer forecast to breakeven Feb 03
High number of new and inexperienced directors Feb 01
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 Jan 23
Independent Non-Executive Director recently bought AU$135k worth of stock Dec 19 ImpediMed Limited Announces CFO Changes
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 Oct 24
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 Oct 12
High number of new directors Oct 05
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer Sep 27
Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022) Aug 31
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 Aug 18
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 Jul 17
ImpediMed Limited Appoints Daniel Sharp as Director Jul 06
Executive Director recently bought AU$144k worth of stock Jun 28
Independent Non-Executive Chairman recently bought AU$82k worth of stock Jun 14
No longer forecast to breakeven May 30
MD, CEO & Director recently bought AU$52k worth of stock Apr 22
MD, CEO & Director recently bought AU$54k worth of stock Mar 31
MD, CEO & Director recently bought AU$64k worth of stock Mar 08
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) Feb 25
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 24
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival Dec 16 Impedimed Limited Announces CEO Changes
ImpediMed Limited Announces Management Changes Nov 22
Less than half of directors are independent Nov 17
Executive Director & Interim CEO recently bought AU$164k worth of stock Nov 01
Less than half of directors are independent Oct 29
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema Oct 27
ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022 Oct 13
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer Oct 12
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients Oct 05
ImpediMed Limited Announces Board Changes Aug 30
Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021) Aug 30
ImpediMed Limited, Annual General Meeting, Oct 26, 2022 Aug 29
Less than half of directors are independent Jul 28
ImpediMed Limited Announces Executive Changes Jul 27 ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director
ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform Jun 02
No longer forecast to breakeven Apr 27
ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022 Apr 22
New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference Mar 07
No longer forecast to breakeven Mar 05
First half 2022 earnings: EPS in line with expectations, revenues disappoint Mar 01
Now 22% undervalued Feb 15
Forecast to breakeven in 2024 Sep 23
FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure Aug 31
Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020) Aug 26
Impedimed Announces Next Generation of Sozo® Digital Health Platform Software Jun 08
ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software May 25
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020) Feb 23
ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021 Jan 21
ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up Jan 12 Impedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention Program
ImpediMed Limited Secures First Commercial Heart Failure Sales Nov 18
ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention Program Nov 16
AstraZeneca Selects SOZO for Second Large Renal Trial Nov 09
HFSA Poster Supports HF-Dex in the Management of HF Patients Oct 04
Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from Lymphedema Oct 03
Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZeneca Sep 30
ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index Sep 21
ImpediMed Limited Auditor Raises 'Going Concern' Doubt Sep 01
Earnings released Aug 26
ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020 Jul 21
ImpediMed Limited announced that it has received AUD 0.227339 million in funding Jul 07 Shareholder Returns IPD AU Medical Equipment AU Market 7D -2.7% 0.7% 1.4% 1Y -44.3% 8.2% 9.2%
See full shareholder returns
Return vs Market: IPD underperformed the Australian Market which returned 9.2% over the past year.
Price Volatility Is IPD's price volatile compared to industry and market? IPD volatility IPD Average Weekly Movement 5.4% Medical Equipment Industry Average Movement 10.3% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.3% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: IPD has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IPD's weekly volatility (5%) has been stable over the past year.
About the Company ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
Show more ImpediMed Limited Fundamentals Summary How do ImpediMed's earnings and revenue compare to its market cap? IPD fundamental statistics Market cap AU$111.34m Earnings (TTM ) -AU$19.79m Revenue (TTM ) AU$10.32m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IPD income statement (TTM ) Revenue AU$10.32m Cost of Revenue AU$1.31m Gross Profit AU$9.01m Other Expenses AU$28.80m Earnings -AU$19.79m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0098 Gross Margin 87.27% Net Profit Margin -191.78% Debt/Equity Ratio 0%
How did IPD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 09:24 End of Day Share Price 2025/01/31 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImpediMed Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dennis Hulme APP Securities Pty Ltd. Matthijs Smith Canaccord Genuity Elyse Shapiro Canaccord Genuity
Show 5 more analysts 
